Palatin Technologies (PTN) Other Non-Current Liabilities (2015 - 2024)
Palatin Technologies' (PTN) quarterly Other Non-Current Liabilities came in at $1.1 million in Q3 2024, down 45.41% YoY from $2.0 million in Q4 2023, and up 7.21% on a QoQ basis from $1.0 million in Q1 2024.
Palatin Technologies (PTN) Other Non-Current Liabilities (2015 - 2024) Analysis & Trends
Palatin Technologies (PTN) has 10 years of Other Non-Current Liabilities data on file, last reported at $1.1 million in Q3 2024.
- Quarterly Other Non-Current Liabilities fell 45.41% year-over-year to $1.1 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.1 million (down 45.41% YoY) and the FY2023 annual result came in at $1.9 million, down 35.32% from the prior year.
- Other Non-Current Liabilities grew to $1.1 million in Q3 2024, from $1.0 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $10.8 million in Q4 2020 to a low of $9062.0 in Q1 2020.
- A 5-year average of $3.9 million and a median of $3.0 million in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2020 — Other Non-Current Liabilities soared 80247.72% — and 2024, when it slumped 72.63%.
- Tracing PTN's Other Non-Current Liabilities over 5 years: stood at $10.8 million in 2020, then sank by 72.19% to $3.0 million in 2021, then advanced by 23.87% to $3.7 million in 2022, then plunged by 70.35% to $1.1 million in 2023, then changed by 0.0% to $1.1 million in 2024.
- The last three Other Non-Current Liabilities figures came in at $1.1 million (Q3 2024), $1.0 million (Q1 2024), and $1.1 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.11 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 1.11 Mn |
| Sep 30, 2023 | 2.03 Mn |
| Jun 30, 2023 | 1.85 Mn |
| Mar 31, 2023 | 3.77 Mn |
| Dec 31, 2022 | 3.73 Mn |
| Sep 30, 2022 | 2.74 Mn |
| Jun 30, 2022 | 2.86 Mn |
| Mar 31, 2022 | 3.00 Mn |
| Dec 31, 2021 | 3.01 Mn |
| Sep 30, 2021 | 6.17 Mn |
| Jun 30, 2021 | 6.23 Mn |
| Mar 31, 2021 | 6.97 Mn |
| Dec 31, 2020 | 10.84 Mn |
| Sep 30, 2020 | 10.62 Mn |
| Mar 31, 2020 | 9,062.00 |
| Dec 31, 2019 | 13,488.00 |
| Jun 30, 2018 | 456,038.00 |
| Mar 31, 2018 | 909,179.00 |